Wednesday, August 5, 2020
Serving the Residents of Las Vegas, Nevada and Clark County


AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020.

United States, California, Redwood City – 06-18-2020 (PRDistribution.com) — AltruBio Inc. www.altrubio.com, a clinical stage biotech company, presented its findings…

By Editorial Team , in PR , at June 24, 2020

United States, California, Redwood City – 06-18-2020 (PRDistribution.com) — AltruBio Inc. www.altrubio.com, a clinical stage biotech company, presented its findings of Neihulizumab, a biologic for the treatment of refractory ulcerative colitis, at DDW in May 2020. Led by gastroenterologist Dr. David T. Rubin of the University of Chicago Medicine, this single-arm, open-label Phase 2 study demonstrated a response rate of 50% (remission rate of 29%) at week 12 after patients with ulcerative colitis received 10 doses of Neihulizumab treatment. The durability of the drug remained at week 26 with a response rate of 50% (remission rate of 30%). AltruBio’s poster was selected as a poster of distinction, meaning that the abstract was scored in the top 10% of all AGA abstracts selected for poster presentation at DDW.

About Neihulizumab.

Neihulizumab is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes chronically activated T cells. This mechanism has been evaluated in four autoimmune and inflammatory diseases and has demonstrated clinical proof of concept and safety in more than 100 patients with psoriasis and psoriatic arthritis. This study drug is currently in Phase 2 trials for the treatment of refractory ulcerative colitis and in Phase 1 trials for the treatment of steroid refractory acute Graft versus Host Disease (SR-aGVHD), with encouraging results in patients that are refractory to available therapies.

About Ulcerative Colitis.

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) that causes chronic inflammation and frequently involves ulceration or erosions in the lining of the colon and rectum. It is estimated that about 1 million people in North America are affected with UC, with incidence rising globally.

Though the etiology is unknown, UC is thought to occur from a combination of genetic and environmental factors. Symptoms include abdominal pain, diarrhea, frequent bowel movements and rectal bleeding. Patients with UC are at higher risk for developing colon cancer.

The information presented here is not intended nor implied to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the advice of your physician or other qualified healthcare professional with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it. 

About AltruBio Inc. (www.altrubio.com

AltruBio is a privately held biotechnology company headquartered in the San Francisco Bay Area that is focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’s pipeline includes two clinical stage product candidates: (i) Neihulizumab (AbGn-168H) an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. AbGn-107 has demonstrated encouraging results in chemo-refractory gastric, pancreatic, colorectal and biliary cancers.

Note on Forward-Looking Statements 

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as expects, believes, intends, and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, and risks related to the Company’s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

Media Contacts:

Company Name: AltruBio Inc.
Full Name: Edwin Powers
Phone: 650-832-1752
Email Address: Send Email
Website: https://www.altrubio.com/altrubio/en

For the original news story, please visit https://prdistribution.com/news/altrubio-s-presentation-on-neihulizumab-phase-2a-ulcerative-colitis-results-selected-as-poster-of-distinction-at-digestive-disease-week-ddw-2020-2.html.